Should I Buy TMO? TMO 2026 Analysis

Should You Buy Thermo Fisher Scientific Inc (TMO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

570.090

1 Day change

-2.01%

52 Week Range

643.990

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor. The stock is oversold and near support, but momentum is still deteriorating (bearish MACD expansion) and the post-earnings guidance hit can keep pressure on price. Without proprietary buy signals, the risk of a further leg down toward the next support outweighs the immediate upside.

Technical Analysis

Price/Trend: TMO sold off (regular session -2.29%) and is trading around 578.6 post-market, which is below S1 (~583.6) and closer to the next support zone S2 (~566.7). Momentum: RSI(6) ~19.2 is deeply oversold (bounce risk), but MACD histogram (-5.671) is below zero and negatively expanding, implying downside momentum is still strengthening. Moving averages are converging, suggesting the stock is in a transition zone, but not yet showing a confirmed reversal. Key levels: Pivot ~611 is now a major overhead resistance; bulls likely need to reclaim that area to re-establish upside control.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call of 0.81 suggests more call OI than puts (mildly constructive longer positioning), but today’s put/call volume of 1.85 indicates near-term traders leaned bearish around this move.

Volatility: 30D IV ~27.7 vs historical vol ~18.1 implies options are priced rich; the market is assigning elevated near-term uncertainty (consistent with post-earnings/guidance repricing).

Technical Summary

Sell

Buy

Positive Catalysts

Q4 2025 beat: Revenue ~$12.21B and adj. EPS $6.57 came in strong versus expectations. Street narrative: multiple firms cite a continuing recovery/normalization into 2026 (biopharma spend improving, tools setup). Analyst support: a wave of price target increases and reiterated Buy/Overweight/Outperform ratings can provide a sentiment backstop after the drop.

Neutral/Negative Catalysts

with bearish MACD expansion raises odds of a retest toward ~566.
Insider activity: insiders are selling, with selling amount up ~226% over the last month—often a sentiment headwind. Margin pressure: gross margin down ~10.33% YoY in the latest quarter suggests mix/cost pressures despite revenue/EPS growth.

Financial Performance

Latest quarter: 2025/Q4. Growth: Revenue $12.215B (+7.20% YoY), Net Income $1.964B (+7.32% YoY), EPS $5.21 (+9.00% YoY) show solid top-line and earnings expansion. Watch-out: Gross margin fell to ~37.95% (-10.33% YoY), indicating profitability headwinds even as sales rise—this aligns with why forward guidance sensitivity mattered to the market.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: decisively improving. Multiple banks raised price targets recently (e.g., Barclays to $650, Citi to $685, Stifel to $700, TD Cowen to $696, BofA to $700, Wells Fargo to $675, KeyBanc upgrade with $750) with predominantly Buy/Overweight/Outperform stances. Wall Street pros: recovery/normalization into 2026, improved biopharma spending, and TMO’s execution and positioning across tools/manufacturing. Cons: timing uncertainty in drug discovery and some government/academic spending pockets, plus near-term guidance/margin concerns that can cap the stock until visibility improves.

19 Analyst Rating

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580 USD and a high forecast of 750 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Buy

1 Hold

0 Sell

Strong Buy

Current: 581.770

Low

580

Averages

658.89

High

750

Current: 581.770

Low

580

Averages

658.89

High

750

Baird

Outperform

maintain

$645 -> $653

AI Analysis

2026-01-30

New

Reason

Baird

Price Target

$645 -> $653

AI Analysis

2026-01-30

New

maintain

Outperform

Reason

Baird raised the firm's price target on Thermo Fisher to $653 from $645 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results and it remains a top idea.

UBS

Neutral

maintain

$590 -> $615

2026-01-30

New

Reason

UBS

Price Target

$590 -> $615

2026-01-30

New

maintain

Neutral

Reason

UBS raised the firm's price target on Thermo Fisher to $615 from $590 and keeps a Neutral rating on the shares. Thermo Fisher's 2026 outlook is in-line with the firm's expectations, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TMO

Unlock Now

TMO Should I Buy

TMO Should I Buy

Should You Buy Thermo Fisher Scientific Inc (TMO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch